(Q40483437)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15585383%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

title

Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15585383%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

pancreatic adenocarcinoma

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15585383%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

J Pablo Arnoletti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15585383%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Zhi-qiang Huang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15585383%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Ashley E Hawkins

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15585383%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Muhamad B Khazaeli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15585383%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Matthias H Kraus

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15585383%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Selwyn M Vickers

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15585383%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

1 December 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15585383%20AND%20SRC:MED&resulttype=core&format=json

Journal of Gastrointestinal Surgery

6 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15585383%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15585383%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15585383%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

960-9; discussion 969-70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15585383%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1016/j.gassur.2004.09.021

6 January 2020

exact match

0 references

cites work

Therapeutics targeting signal transduction for patients with colorectal carcinoma

1 reference

12 December 2020

Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product

1 reference

12 December 2020

Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation

1 reference

12 December 2020

Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression

1 reference

12 December 2020

The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

1 reference

12 December 2020

The EGF receptor family as targets for cancer therapy

1 reference

12 December 2020

The epidermal growth factor receptor as a target for cancer therapy

1 reference

12 December 2020

Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody

1 reference

12 December 2020

Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complex

1 reference

12 December 2020

ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases

1 reference

12 December 2020

Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer

1 reference

12 December 2020

Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

1 reference

12 December 2020

Conjugated linoleic acid inhibits cell proliferation and ErbB3 signaling in HT-29 human colon cell line

1 reference

12 December 2020

Specificity within the EGF family/ErbB receptor family signaling network

1 reference

12 December 2020

Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness

1 reference

12 December 2020

The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4

1 reference

12 December 2020

Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas

1 reference

12 December 2020

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

12 December 2020

Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects

1 reference

12 December 2020

Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice

1 reference

12 December 2020

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

1 reference

12 December 2020

ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor

1 reference

12 December 2020

Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells

1 reference

12 December 2020

Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers

1 reference

12 December 2020

Immune responses to all ErbB family receptors detectable in serum of cancer patients

1 reference

12 December 2020

Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors

1 reference

12 December 2020

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

1 reference

12 December 2020

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

12 December 2020

Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members

1 reference

12 December 2020

Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms

1 reference

12 December 2020

Mechanisms and consequences of activation of protein kinase B/Akt

1 reference

12 December 2020

Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha

1 reference

12 December 2020

Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas

1 reference

12 December 2020